Altman Peter purchased $2K of BCDA
Altman Peter (President and CEO) purchased 1,900 shares of BioCardia, Inc. (BCDA) at $0.92 on 2026-08-13.
How this was made
The 30-second read
Why it matters
The only new fact is the CEO’s open-market purchase details (shares, price, total value, and post-transaction holdings). There is no guidance, deal, clinical update, or regulatory action included.
Market read
Traders may note the insider buy as a minor sentiment input, but it does not change fundamentals based on the provided text.
What to watch
The filing notes no pre-arranged 10b5-1 plan, but it still does not disclose the motivation, timing constraints, or whether the purchase is part of a broader pattern.
Background
This is a SEC Form 4 insider transaction disclosure for BioCardia, Inc. (BCDA).
Ticker impact
BioCardia CEO Altman Peter filed a Form 4 open-market purchase of 1,900 shares at $0.9200 on 2026-08-13.
Likely minimal near-term price impact; any effect would be sentiment-driven and short-lived.
Form 4 insider purchases can be read as confidence, but the disclosed size ($1,748) is modest and the filing provides no new operational or financial information.
Market effects
No clear sector read-through from a small CEO open-market purchase without accompanying company fundamentals.
None indicated.
None indicated.
Counterpoint
Insider buys on Form 4 can reflect routine liquidity needs or diversification rather than a strong forward-looking signal, especially when the dollar amount is small.
Key entities
- issuerBioCardia, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderAltman Peter
President and CEO who reported the open-market purchase.
